Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Wenhao Luo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9914-5338; OpenAlex author ID A5000119086. Sources: OpenAlex.

Their work

Papers
30 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2019: 2 papers · 2020: 4 papers · 2021: 7 papers · 2022: 2 papers · 2023: 5 papers · 2024: 7 papers · 2025: 1 paper · 2026: 2 papers

Papers 30

  1. TRDMT1-mediated mRNA m5C methylation decreases chemotherapy sensitivity by activating homologous recombination-mediated DNA damage repair and IRS2 expression i… Co-author DOI 10.1016/j.canlet.2026.218725↗
  2. Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study. Co-author DOI 10.1038/s41392-026-02741-1↗
  3. SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. Co-author DOI 10.1002/mc.23936↗
  4. The new era of pancreatic cancer treatment: Application of nanotechnology breaking through bottlenecks. Co-author DOI 10.1016/j.canlet.2024.216979↗
  5. E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation. Co-author DOI 10.1016/j.freeradbiomed.2024.05.031↗
  6. The NF-κB/NUAK2 signaling axis regulates pancreatic cancer progression by targeting SMAD2/3. Co-author DOI 10.1016/j.isci.2024.109406↗
  7. FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis. Co-author DOI 10.1158/0008-5472.can-23-3638↗
  8. Unbiasedly decoding the tumor microenvironment with single-cell multiomics analysis in pancreatic cancer. Co-author DOI 10.1186/s12943-024-02050-7↗
  9. CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. Co-author DOI 10.1186/s13046-024-03201-w↗
  10. Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic Cancer. Co-author DOI 10.2147/cmar.s465098↗
  11. Cancer-associated fibroblasts: A key target to snatch victory from defeat in therapy resistance associated with the pancreatic cancer stroma. Co-author DOI 10.1016/j.canlet.2023.216279↗
  12. Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. Co-author DOI 10.1016/j.canlet.2023.216423↗
  13. PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. Co-author DOI 10.1016/j.heliyon.2023.e17194↗
  14. Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC). First author DOI 10.1016/j.heliyon.2023.e20969↗
  15. Does Oral Microbiota Have a Close Relationship with Pancreatic Cancer? A Systematic Review and Meta-Analysis. First author DOI 10.1245/s10434-023-14366-7↗
  16. Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer. Co-author DOI 10.1186/s12935-022-02583-1↗
  17. Is neoadjuvant chemoradiotherapy for pancreatic cancer beneficial: A systematic review and meta-analysis. Co-author DOI 10.3389/fonc.2022.979390↗
  18. Novel therapeutic strategies and perspectives for pancreatic cancer: Autophagy and apoptosis are key mechanisms to fight pancreatic cancer. Co-author DOI 10.1007/s12032-021-01522-w↗
  19. Do novel treatment strategies enhance T cell-mediated Immunity: Opportunities and challenges in pancreatic cancer immunotherapy. Co-author DOI 10.1016/j.intimp.2020.107199↗
  20. Targeting hypoxic tumor microenvironment in pancreatic cancer. Co-author DOI 10.1186/s13045-020-01030-w↗
  21. Novel therapies targeting hypoxia mechanism to treat pancreatic cancer. Co-author DOI 10.21147/j.issn.1000-9604.2021.02.09↗
  22. Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.596573↗
  23. The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. Co-author DOI 10.3390/cells10030497↗
  24. [Challenges and stratigies of neoadjuvant therapy for pancreatic cancer]. First author DOI 10.3760/cma.j.cn112137-20201225-03469↗
  25. Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.05.003↗
  26. Novel Discoveries Targeting Pathogenic Gut Microbes and New Therapies in Pancreatic Cancer: Does Pathogenic E. coli Infection Cause Pancreatic Cancer Progressi… Co-author DOI 10.1155/2020/2340124↗
  27. Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory. Co-author DOI 10.1186/s12935-020-1147-9↗
  28. Current epidemiology of pancreatic cancer: Challenges and opportunities. Co-author DOI 10.21147/j.issn.1000-9604.2020.06.04↗
  29. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? Co-author DOI 10.1002/cam4.2384↗
  30. Low hENT1 expression indicates poor prognosis in gemcitabine-treated pancreatic cancer patients Co-author DOI 10.21203/rs.2.17850/v1↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taiping Zhang · 26 shared papers, 2019–2026 · strength 5.01
  2. Jiangdong Qiu · 15 shared papers, 2019–2025 · strength 2.39
  3. Yueze Liu · 14 shared papers, 2019–2026 · strength 2.22
  4. Jinxin Tao · 10 shared papers, 2020–2025 · strength 1.79
  5. Lei You · 10 shared papers, 2019–2026 · strength 1.34
  6. Gang Yang · 9 shared papers, 2019–2024 · strength 1.19
  7. Zhe Cao · 8 shared papers, 2019–2026 · strength 1.14
  8. Fangyu Zhao · 9 shared papers, 2019–2024 · strength 1.13
  9. Jianchun Xiao · 7 shared papers, 2019–2026 · strength 1.10
  10. Yupei Zhao · 7 shared papers, 2019–2026 · strength 1.03
  11. Ruobing Wang · 5 shared papers, 2023–2024 · strength 0.97
  12. Jiangdong Qiu · 5 shared papers, 2019–2026 · strength 0.86
  13. Yifan Fu · 4 shared papers, 2024–2026 · strength 0.78
  14. Guangyu Chen · 5 shared papers, 2020–2024 · strength 0.66
  15. Hua Huang · 4 shared papers, 2021–2025 · strength 0.66
  16. Hao Chen · 3 shared papers, 2020–2026 · strength 0.62
  17. Dan Su · 3 shared papers, 2023–2024 · strength 0.56
  18. Tao Liu · 3 shared papers, 2024–2025 · strength 0.55
  19. Haowei Ma · 2 shared papers, 2023 · strength 0.48
  20. Zhe Cao · 2 shared papers, 2025–2026 · strength 0.43
  21. Yuanyang Wang · 2 shared papers, 2024–2025 · strength 0.39
  22. Mengyu Feng · 3 shared papers, 2019–2023 · strength 0.37
  23. Jun Wang · 2 shared papers, 2023–2025 · strength 0.37
  24. Dan Su · 2 shared papers, 2024 · strength 0.35
  25. Yu Lan Gu · 1 shared paper, 2023 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.